Evolução clínica de pacientes com Prolactinoma tratados com Cabergolina no Hospital Universitário João de Barros Barreto no período de 2003 a 2007

Abstract

Prolactinomas are the most frequent pituitary tumors. The prolactinoma`s treatment is mainly done with the dopaminergic agonist. Cabergoline (CAB) is a long-acting ergoline dopaminergic agonist for oral administration, already described as a useful drug for hyperprolactinemia therapy. This study aims to analyze the clinical’s evolution about patients with prolactinoma treatise with cabergoline in the Hospital`s University João of Barros Barreto (HUJBB), in Belém-PA. It’s a transversal and observational study realized through the analysis of 56 patient’s registers matriculated in HUJBB, at the period of 2003 to 2007, across of register’s research. The variables studied were: age, sex, time between the first symptom and diagnostic, symptoms and signals presented, laboratorial’s data about hyperprolactinemia and its evolution, size of prolactinoma,, time of treatment with CAB and the clinicals, laboratorials and radiologic’s efects related to the administration of CAB, as well as some aspects of the drugs` pharmacology. This study passed the CEP of HUJBB. Results: Prevalence of feminine sex at the proportion of 7:1; symptoms most frequent in diagnostic were: galactorrhea (80.3%), head-ache (73,21%), amenorrhea (69,64%), and others sexual`s symptoms (48,21%). All of the patients makes dosage of prolactine and realized too a test of image (RNM or/and TC); The dosage of Cabergoline varied of 0,25 to 1,0 mg/week in 55,36% of the cases, on the time of treatment of one to two years in 42,86% of the cases, and more two years on 33,93%. 17,83% of the patients presented collateral’s effects with the treatment of the drug. Serum prolactin`s levels normalized in 60,71% of the cases and reduced the prolactnemia in all of patients. Observed yet betterment of galactorrhea (84,44%), sexual symptoms (81,82%), amenorrhea (69,23%) and other symptoms (80,36%). Concluded that the patients presented a good clinical and laboratorial evolution, and that the CAB is emerging as the important alternative in the treatment of prolactinomas.